These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24488422)

  • 1. Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR.
    Mackie SL; Arat S; da Silva J; Duarte C; Halliday S; Hughes R; Morris M; Pease CT; Sherman JW; Simon LS; Walsh M; Westhovens R; Zakout S; Kirwan JR
    J Rheumatol; 2014 Apr; 41(4):819-23. PubMed ID: 24488422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group.
    Helliwell T; Brouwer E; Pease CT; Hughes R; Hill CL; Neill LM; Halls S; Simon LS; Mallen CD; Boers M; Kirwan JR; Mackie SL
    J Rheumatol; 2016 Jan; 43(1):182-6. PubMed ID: 26568595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome Measures in Polymyalgia Rheumatica. A Systematic Review.
    Duarte C; Ferreira RJ; Mackie SL; Kirwan JR; Pereira da Silva JA;
    J Rheumatol; 2015 Dec; 42(12):2503-11. PubMed ID: 26568600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "I suddenly felt I'd aged": a qualitative study of patient experiences of polymyalgia rheumatica (PMR).
    Twohig H; Mitchell C; Mallen C; Adebajo A; Mathers N
    Patient Educ Couns; 2015 May; 98(5):645-50. PubMed ID: 25638304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes Measured in Polymyalgia Rheumatica and Measurement Properties of Instruments Considered for the OMERACT Core Outcome Set: A Systematic Review.
    Twohig H; Owen C; Muller S; Mallen CD; Mitchell C; Hider S; Hill C; Shea B; Mackie SL
    J Rheumatol; 2021 Jun; 48(6):883-893. PubMed ID: 32739892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of polymyalgia rheumatica: a systematic review.
    Hernández-Rodríguez J; Cid MC; López-Soto A; Espigol-Frigolé G; Bosch X
    Arch Intern Med; 2009 Nov; 169(20):1839-50. PubMed ID: 19901135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica.
    Mackie SL; Twohig H; Neill LM; Harrison E; Shea B; Black RJ; Kermani TA; Merkel PA; Mallen CD; Buttgereit F; Mukhtyar C; Simon LS; Hill CL;
    J Rheumatol; 2017 Oct; 44(10):1515-1521. PubMed ID: 28765246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
    Buttgereit F; Dejaco C; Matteson EL; Dasgupta B
    JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward a Core Outcome Measurement Set for Polymyalgia Rheumatica: Report from the OMERACT 2018 Special Interest Group.
    Owen CE; Yates M; Twohig H; Muller S; Neill LM; Harrison E; Shea B; Simon LS; Hill CL; Mackie SL
    J Rheumatol; 2019 Oct; 46(10):1360-1364. PubMed ID: 30709960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial.
    Marsman DE; Bolhuis TE; den Broeder N; den Broeder AA; van der Maas A
    Trials; 2022 Apr; 23(1):318. PubMed ID: 35428320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice.
    Cleuziou C; Binard A; De Bandt M; Berthelot JM; Saraux A
    J Rheumatol; 2012 Feb; 39(2):310-3. PubMed ID: 22174199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission.
    Leeb BF; Rintelen B; Sautner J; Fassl C; Bird HA
    Arthritis Rheum; 2007 Jun; 57(5):810-5. PubMed ID: 17530664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma fibrinogen along with patient-reported outcome measures enhances management of polymyalgia rheumatica: a prospective study.
    McCarthy EM; MacMullan PA; Al-Mudhaffer S; Madigan A; Donnelly S; McCarthy CJ; Molloy ES; Kenny D; McCarthy GM
    J Rheumatol; 2014 May; 41(5):931-7. PubMed ID: 24692520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus.
    Dejaco C; Duftner C; Cimmino MA; Dasgupta B; Salvarani C; Crowson CS; Maradit-Kremers H; Hutchings A; Matteson EL; Schirmer M;
    Ann Rheum Dis; 2011 Mar; 70(3):447-53. PubMed ID: 21097803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study.
    Yates M; Owen CE; Muller S; Graham K; Neill L; Twohig H; Boers M; Pujades Rodriguez M; Goodman SM; Cheah J; Dejaco C; Mukhtyar C; Nielsen BD; Robson J; Simon LS; Shea B; Mackie SL; Hill CL;
    J Rheumatol; 2020 Sep; 47(9):1379-1384. PubMed ID: 32007937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of pain and stiffness with fatigue in incident polymyalgia rheumatica: baseline results from the polymyalgia rheumatica cohort study.
    Prior JA; Muller S; Helliwell T; Hider SL; Barraclough K; Dasgupta B; Mallen CD
    Prim Health Care Res Dev; 2019 May; 20():e46. PubMed ID: 32799976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes in polymyalgia rheumatica.
    Matteson EL; Maradit-Kremers H; Cimmino MA; Schmidt WA; Schirmer M; Salvarani C; Bachta A; Dejaco C; Duftner C; Slott Jensen H; Poór G; Kaposi NP; Mandl P; Balint PV; Schmidt Z; Iagnocco A; Cantini F; Nannini C; Macchioni P; Pipitone N; Del Amo M; Espígol-Frigolé G; Cid MC; Martínez-Taboada VM; Nordborg E; Direskeneli H; Aydin SZ; Ahmed K; Hazelman B; Pease C; Wakefield RJ; Luqmani R; Abril A; Marcus R; Gonter NJ; Maz M; Crowson CS; Dasgupta B
    J Rheumatol; 2012 Apr; 39(4):795-803. PubMed ID: 22422492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Test-retest reliability of pain VAS/NRS, stiffness VAS/NRS, HAQ-DI and mHAQ in polymyalgia rheumatica: An OMERACT study.
    Leung JL; Twohig H; Muller S; Maxwell L; Mackie SL; Neill LM; Owen CE;
    Semin Arthritis Rheum; 2023 Oct; 62():152239. PubMed ID: 37429139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives and unmet needs in polymyalgia rheumatica. Providing the fundamental framework for the development of new treatment regimes in polymyalgia rheumatica.
    Nielsen BD; Dasgupta B
    Reumatismo; 2018 Mar; 70(1):1-9. PubMed ID: 29589397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica.
    Dejaco C; Singh YP; Perel P; Hutchings A; Camellino D; Mackie S; Matteson EL; Dasgupta B
    Ann Rheum Dis; 2015 Oct; 74(10):1808-17. PubMed ID: 26359489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.